Dr. Stehman-Breen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1030 Massachusetts Ave
Cambridge, MA 02138Phone+1 805-890-4210
Education & Training
University of WashingtonFellowship, Nephrology, 1993 - 1997
University of WashingtonMaster in Public Health, 1994 - 1996- University of WashingtonResidency, Internal Medicine, 1990 - 1993
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1990
Certifications & Licensure
WA State Medical License 1992 - 2025
Clinical Trials
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD) Start of enrollment: 2018 Feb 05
- Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY) Start of enrollment: 2019 Jul 03
Publications & Presentations
PubMed
- 148 citationsRisk of Death Among Chronic Dialysis Patients Infected With Hepatitis C VirusCatherine Stehman-Breen, Scott S. Emerson, David R. Gretch, Richard J. Johnson
American Journal of Kidney Diseases. 1998-10-01 - 397 citationsCystatin C and Prognosis for Cardiovascular and Kidney Outcomes in Elderly Persons without Chronic Kidney DiseaseMichael G. Shlipak, Ronit Katz, Mark J. Sarnak, Linda F. Fried, Anne B. Newman
Annals of Internal Medicine. 2006-08-15 - 271 citationsThe presence of frailty in elderly persons with chronic renal insufficiency.Michael G. Shlipak, Catherine Stehman-Breen, Linda F. Fried, Xiao Song, David S. Siscovick
American Journal of Kidney Diseases. 2004-05-01
Press Mentions
Chutes & Ladders—Vertex CMO Kewalramani Steps into Pharma's Exclusive Female CEO ClubJuly 26th, 2019
Dyne Therapeutics Appoints Catherine Stehman-Breen to Its Board of DirectorsJune 28th, 2019
Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. As Chief Medical OfficerApril 3rd, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
